Compare OI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OI | RCKT |
|---|---|---|
| Founded | 1903 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 340.9M |
| IPO Year | N/A | N/A |
| Metric | OI | RCKT |
|---|---|---|
| Price | $14.74 | $3.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $16.29 | ★ $29.12 |
| AVG Volume (30 Days) | ★ 2.9M | 2.0M |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,455,000,000.00 | N/A |
| Revenue This Year | $1.41 | N/A |
| Revenue Next Year | $1.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.23 | $2.19 |
| 52 Week High | $16.04 | $13.35 |
| Indicator | OI | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 46.08 |
| Support Level | $15.00 | $3.30 |
| Resistance Level | $15.34 | $3.57 |
| Average True Range (ATR) | 0.48 | 0.18 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 62.18 | 22.81 |
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.